- Home
- RCUS vs KEN Comparison
RCUS vs KEN Comparison
Compare RCUS & KEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- KEN
- Stock Information
- Founded
- RCUS 2015
- KEN 2014
- Country
- RCUS United States
- KEN Singapore
- Employees
- RCUS N/A
- KEN N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- KEN Electric Utilities: Central
- Sector
- RCUS Health Care
- KEN Utilities
- Exchange
- RCUS Nasdaq
- KEN Nasdaq
- Market Cap
- RCUS 906.4M
- KEN 1.8B
- IPO Year
- RCUS 2018
- KEN N/A
- Fundamental
- Price
- RCUS $8.47
- KEN $44.00
- Analyst Decision
- RCUS Buy
- KEN
- Analyst Count
- RCUS 10
- KEN 0
- Target Price
- RCUS $23.75
- KEN N/A
- AVG Volume (30 Days)
- RCUS 1.1M
- KEN 22.6K
- Earning Date
- RCUS 08-07-2025
- KEN 05-28-2025
- Dividend Yield
- RCUS N/A
- KEN 10.96%
- EPS Growth
- RCUS N/A
- KEN N/A
- EPS
- RCUS N/A
- KEN 11.35
- Revenue
- RCUS $141,000,000.00
- KEN $760,304,000.00
- Revenue This Year
- RCUS N/A
- KEN N/A
- Revenue Next Year
- RCUS $28.73
- KEN N/A
- P/E Ratio
- RCUS N/A
- KEN $3.78
- Revenue Growth
- RCUS N/A
- KEN 5.78
- 52 Week Low
- RCUS $6.50
- KEN $23.31
- 52 Week High
- RCUS $18.98
- KEN $43.78
- Technical
- Relative Strength Index (RSI)
- RCUS 45.47
- KEN 82.05
- Support Level
- RCUS $7.92
- KEN $42.20
- Resistance Level
- RCUS $8.81
- KEN $39.69
- Average True Range (ATR)
- RCUS 0.45
- KEN 0.73
- MACD
- RCUS -0.06
- KEN 0.51
- Stochastic Oscillator
- RCUS 39.02
- KEN 96.10
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.